National Advertising Division Recommends Certain Health-Related Claims for MagniLife Knee Pain Relief Soothing Gel be Discontinued
New York, NY – March 6, 2025 – As part of its marketplace monitoring efforts, BBB National Programs’ National Advertising Division recommended that The Magni Group, Inc. discontinue certain claims regarding the ability of its MagniLife Knee Pain Relief Soothing Gel to provide fast pain relief.
MagniLife Gel is touted as quickly relieving pain, swelling, and inflammation from sore muscles, joint discomfort, and injuries. The challenged claims appeared on product packaging, in direct mail advertisements, as well as online and on social media.
The National Advertising Division (NAD) noted that where the substantiation in the record consists solely of evidence regarding the efficacy of ingredients in a product, but not for the product itself, the advertising must not suggest or imply that the product provides the claimed benefits.
NAD determined that since The Magni Group lacked any testing on the product itself, it did not have a reasonable basis for unqualified claims that the product provides the challenged benefits and recommended that it discontinue the following claims:
Further, NAD also considered whether The Magni Group’s evidence could support qualified claims regarding the efficacy of the product’s ingredients, however it concluded that such evidence was not reliable support for the claimed benefits of MagniLife Gel’s ingredients.
In its advertiser statement, The Magni Group stated that it agrees to comply with NAD’s decision.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.
MagniLife Gel is touted as quickly relieving pain, swelling, and inflammation from sore muscles, joint discomfort, and injuries. The challenged claims appeared on product packaging, in direct mail advertisements, as well as online and on social media.
The National Advertising Division (NAD) noted that where the substantiation in the record consists solely of evidence regarding the efficacy of ingredients in a product, but not for the product itself, the advertising must not suggest or imply that the product provides the claimed benefits.
NAD determined that since The Magni Group lacked any testing on the product itself, it did not have a reasonable basis for unqualified claims that the product provides the challenged benefits and recommended that it discontinue the following claims:
- “Rapid Pain Relief”
- “Relieves stiffness, tenderness, swelling aching and burning pains associated with knee discomfort.”
- “Say goodbye to knee pain without surgery! Fast-acting gel reduces pain, swelling and inflammation from sore muscles, joint discomfort, and injuries. With added support for relief and recovery from proven, all-natural ingredients including Arnica, Dragon's Blood, Cat's Claw and MSM.”
Further, NAD also considered whether The Magni Group’s evidence could support qualified claims regarding the efficacy of the product’s ingredients, however it concluded that such evidence was not reliable support for the claimed benefits of MagniLife Gel’s ingredients.
In its advertiser statement, The Magni Group stated that it agrees to comply with NAD’s decision.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.